Hope Leanne Johnson

Dr. Hope Leanne Johnson

Measurement, Evaluation and Learning, Gavi, Geneva, Genève, Switzerland
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in Vaccine
Verified
Journal Article
Open access
JVJennifer R. Verani
Jennifer R. Verani
ABAbdullah H. Baqui
Abdullah H. Baqui
CBClaire V. Broome
Claire V. Broome
TCThomas Cherian
Thomas Cherian
CCCheryl Cohen
Cheryl Cohen
EZElizabeth R. Zell
Elizabeth R. Zell
Case-control studies are commonly used to evaluate effectiveness of licensed vaccines after deployment in public health programs. Such studies can provide policy-relevant data on vaccine performance under 'real world' conditions, contributing to the evidence base to support and sustain introduction of new vaccines. However, case-control studies do not measure the impact of vaccine introduction on disease at a population level, and are subject to bias and confounding, which may lead to inaccurate results that can misinform policy decisions. In 2012, a group of experts met to review recent experience with case-control studies evaluating the effectiveness of several vaccines; here we summarize the recommendations of that group regarding best practices for planning, design and enrollment of cases and controls. Rigorous planning and preparation should focus on understanding the study context including healthcare-seeking and vaccination practices. Case-control vaccine effectiveness studies are best carried out soon after vaccine introduction because high coverage creates strong potential for confounding. Endpoints specific to the vaccine target are preferable to non-specific clinical syndromes since the proportion of non-specific outcomes preventable through vaccination may vary over time and place, leading to potentially confusing results. Controls should be representative of the source population from which cases arise, and are generally recruited from the community or health facilities where cases are enrolled. Matching of controls to cases for potential confounding factors is commonly used, although should be reserved for a limited number of key variables believed to be linked to both vaccination and disease. Case-control vaccine effectiveness studies can provide information useful to guide policy decisions and vaccine development, however rigorous preparation and design is essential.

1 June 2017 in Vaccine
Verified
Journal Article
Open access
JVJennifer R. Verani
Jennifer R. Verani
ABAbdullah H. Baqui
Abdullah H. Baqui
CBClaire V. Broome
Claire V. Broome
TCThomas Cherian
Thomas Cherian
CCCheryl Cohen
Cheryl Cohen
EZElizabeth R. Zell
Elizabeth R. Zell
The case-control methodology is frequently used to evaluate vaccine effectiveness post-licensure. The results of such studies provide important insight into the level of protection afforded by vaccines in a 'real world' context, and are commonly used to guide vaccine policy decisions. However, the potential for bias and confounding are important limitations to this method, and the results of a poorly conducted or incorrectly interpreted case-control study can mislead policies. In 2012, a group of experts met to review recent experience with case-control studies evaluating vaccine effectiveness; we summarize the recommendations of that group regarding best practices for data collection, analysis, and presentation of the results of case-control vaccine effectiveness studies. Vaccination status is the primary exposure of interest, but can be challenging to assess accurately and with minimal bias. Investigators should understand factors associated with vaccination as well as the availability of documented vaccination status in the study context; case-control studies may not be a valid method for evaluating vaccine effectiveness in settings where many children lack a documented immunization history. To avoid bias, it is essential to use the same methods and effort gathering vaccination data from cases and controls. Variables that may confound the association between illness and vaccination are also important to capture as completely as possible, and where relevant, adjust for in the analysis according to the analytic plan. In presenting results from case-control vaccine effectiveness studies, investigators should describe enrollment among eligible cases and controls as well as the proportion with no documented vaccine history. Emphasis should be placed on confidence intervals, rather than point estimates, of vaccine effectiveness. Case-control studies are a useful approach for evaluating vaccine effectiveness; however careful attention must be paid to the collection, analysis and presentation of the data in order to best inform evidence-based vaccine policies.

28 April 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
Devaki NambiarDevaki Nambiar
Devaki Nambiar
Ahmad Reza HosseinpoorAhmad Reza Hosseinpoor
Ahmad Reza Hosseinpoor
Nicole BergenNicole Bergen
Nicole Bergen
M. Carolina DanovaroM. Carolina Danovaro
M. Carolina Danovaro
Aaron WallaceAaron Wallace
Aaron Wallace
Hope Leanne JohnsonHope Leanne Johnson
Hope Leanne Johnson
Immunization, hailed as one of the most successful public health interventions in the world, has contributed to major advancements in health as well as social and economic development

1 May 2010 in International Journal of STD & AIDS
Verified
Journal Article
Closed access
MSM F Silveira
M F Silveira
EEE J Erbelding
E J Erbelding
KGK G Ghanem
K G Ghanem
Hope Leanne JohnsonHope Leanne Johnson
Hope Leanne Johnson
ABA E Burke
A E Burke
JZJ M Zenilman
J M Zenilman
Our goal was to define the risk factors for Chlamydia trachomatis (CT) infection among pregnant women at a large urban medical centre. In a retrospective study, clinical records at a US maternity unit from July 2005 through February 2008 were reviewed. The study population included all pregnant women with a singleton newborn of at least 20 weeks gestation and antenatal care information. Logistic regression was used to analyse the association between a positive CT test and demographic, behavioural and prenatal care variables. A total of 2127 women were included in this analysis. The prevalence of CT infection was 4.7%. Cases were more likely to be younger, black and single. Other risk factors included tobacco use and Neisseria gonorrhoeae infection. Our findings suggest that factors other than age may impact upon the diagnosis of CT in pregnant women and that a more comprehensive testing strategy should be considered.

1 May 2015 in Vaccine
Verified
Journal Article
Closed access
SSStephen Sosler
Stephen Sosler
JKJudith Kallenberg
Judith Kallenberg
Hope Leanne JohnsonHope Leanne Johnson
Hope Leanne Johnson

27 August 2019 in medRxiv
Verified
Preprint
Open access
PDF file
XLXiaofeng Li
Xiaofeng Li
CMChristinah Mukandavire
Christinah Mukandavire
ZCZulma M Cucunubá
Zulma M Cucunubá
KAKaja Abbas
Kaja Abbas
HCHannah Clapham
Hannah Clapham
(C(Vaccine Impact Modelling Consortium)
(Vaccine Impact Modelling Consortium)
Background: The last two decades have seen substantial expansion of childhood vaccination programmes in low and middle income countries (LMICs). Here we quantify the health impact of these programmes by estimating the deaths and disability-adjusted life years (DALYs) averted by vaccination with ten antigens in 98 LMICs between 2000 and 2030. Methods: Independent research groups provided model-based disease burden estimates under a range of vaccination coverage scenarios for ten pathogens: hepatitis B (HepB), Haemophilus influenzae type b (Hib), human papillomavirus (HPV), Japanese encephalitis (JE), measles, Neisseria meningitidis serogroup A (MenA), Streptococcus pneumoniae , rotavirus, rubella, yellow fever. Using standardized demographic data and vaccine coverage estimates for routine and supplementary immunization activities, the impact of vaccination programmes on deaths and DALYs was determined by comparing model estimates from the no vaccination counterfactual scenario with those from a default coverage scenario. We present results in two forms: deaths/DALYs averted in a particular calendar year, and in a particular annual birth cohort. Findings: We estimate that vaccination will have averted 69 (2.5-97.5% quantile range 52-88) million deaths between 2000 and 2030 across the 98 countries and ten pathogens considered, 35 (29-45) million of these between 2000-2018. From 2000-2018, this represents a 44% (36-57%) reduction in deaths due to the ten pathogens relative to the no vaccination counterfactual. Most (96% (93-97%)) of this impact is in under-five age mortality, notably from measles. Over the lifetime of birth cohorts born between 2000 and 2030, we predict that 122 (96-147) million deaths will be averted by vaccination, of which 58 (39-75) and 38 (26-52) million are due to measles and Hepatitis B vaccination, respectively. We estimate that recent increases in vaccine coverage and introductions of additional vaccines will result in a 72% (61-79%) reduction in lifetime mortality caused by these 10 pathogens in the 2018 birth cohort. Interpretation: Increases in vaccine coverage and the introduction of new vaccines into LMICs over the last two decades have had a major impact in reducing mortality. These public health gains are predicted to increase in coming decades if progress in increasing coverage is sustained.